Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G Johnson, Jiejun Du, Patricia Carmelitano, Michelle L Brown, Amanda Paschke, Carisa De Anda
Infectious Diseases and Therapy, doi:10.1007/s40121-023-00891-1
Introduction: The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of hospitalization/ death in high-risk adults. At the time of that report, virologic assessments from the trial were partially incomplete as a result of their timeintensive nature. Here we present final results from all prespecified virology endpoints in MOVe-OUT based on the full trial dataset.
Supplementary Information The online version contains supplementary material available at https:// doi.org/10.1007/s40121-023-00891- MSD), at the time the study was conducted. Jiejun Du is currently an employee of Moderna, and Jay A. Grobler is currently an employee of Pfizer Inc.
Ethical Approval. Our company's approach to the conduct of clinical trials is in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with Good Clinical Practice and the applicable regulatory requirement(s). The trial was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Abdelnabi, Foo, Jonghe, Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model, J Infect Dis
Agostini, Pruijssers, Chappell, Smallmolecule antiviral beta-d-N(4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance, J Virol
Aksamentov, Roemer, Hodcroft, Nextclade: clade assignment, mutation calling and quality control for viral genomes, J Open Source Softw
Arribas, Bhagani, Lobo, Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19, NEJM Evid,
doi:10.1056/EVIDoa2100044Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Boucau, Marino, Regan, Duration of shedding of culturable virus in SARS-CoV-2 Omicron (BA.1) infection, N Engl J Med
Bowe, Xie, Al-Aly, Acute and postacute sequelae associated with SARS-CoV-2 reinfection, Nat Med
Brown, Fu, Bansal, Omicron BA.1/1.1 SARS-CoV-2 infection among vaccinated Canadian adults, N Engl J Med
Butler, Hobbs, Gbinigie, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial, Lancet
Butt, Talisa, Shaikh, Relative vaccine effectiveness of a SARS-CoV-2 mRNA vaccine booster dose against the Omicron variant, Clin Infect Dis
Caraco, Crofoot, Moncada, Phase 2/3 trial of molnupiravir for treatment of COVID-19 in nonhospitalized adults, NEJM Evid,
doi:10.1056/EVIDoa2100043Cevik, Tate, Llloyd, SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis, Lancet Microbe
Chawla, Birger, Wan, Factors influencing COVID-19 risk: insights from molnupiravir exposure-response modeling of clinical outcomes, Clin Pharmacol Ther
Cox, Wolf, Plemper, Therapeutically administered ribonucleoside analogue MK-4482/ EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, Nat Microbiol
Dal-Re, Becker, Bottieau, Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach, Lancet Infect Dis
Donovan-Banfield, Penrice-Randal, Goldswain, Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE phase IIa clinical trial, Nat Commun
Fischer Wa 2nd, Eron, Jr, Holman, A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med
Goldberg, Mandel, Bar-On, Protection and waning of natural and hybrid immunity to SARS-CoV-2, N Engl J Med
Gordon, Tchesnokov, Schinazi, Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template, J Biol Chem
Grobler, Strizki, Murgolo, Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies, Open Forum Infect Dis
Johnson, Puenpatom, Moncada, Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial, Ann Intern Med
Kabinger, Stiller, Schmitzova, Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat Struct Mol Biol
Kang, Park, Kim, Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: a prospective cohort study, Vaccine
Khoo, Fitzgerald, Saunders, Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebocontrolled, double-blind, phase 2 trial, Lancet Infect Dis
Levin, Lustig, Cohen, Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months, N Engl J Med
Malone, Campbell, Molnupiravir: coding for catastrophe, Nat Struct Mol Biol
Mazzotta, Lepri, Colavita, Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents, J Med Virol
Meng, Abdullahi, Ferreira, Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity, Nature
Perez-Alos, Armenteros, Madsen, Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors, Nat Commun
Puhach, Meyer, Eckerle, SARS-CoV-2 viral load and shedding kinetics, Nat Rev Microbiol
Rosenke, Okumura, Lewis, Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model, JCI Insight
Sethuraman, Jeremiah, Ryo, Interpreting diagnostic tests for SARS-CoV-2, JAMA
Sheahan, Sims, Zhou, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci Transl Med
Singh, Stellrecht, Arunachalam, Lack of active SARS-CoV-2 virus in a subset of PCR-positive COVID-19 congregate care patients, J Clin Virol
Sonnleitner, Dorighi, Jansen, An in vitro model for assessment of SARS-CoV-2 infectivity by defining the correlation between virus isolation and quantitative PCR value: isolation success of SARS-CoV-2 from oropharyngeal swabs correlates negatively with Cq value, Virol J
Ssentongo, Ssentongo, Voleti, SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis, BMC Infect Dis
Takashita, Kinoshita, Yamayoshi, Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant, N Engl J Med
Takashita, Yamayoshi, Simon, Efficacy of antibodies and antiviral drugs against Omicron BA. 2.12.1, BA.4, and BA.5 subvariants, N Engl J Med
Uraki, Kiso, Iida, Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA. 2, Nature
Urakova, Kuznetsova, Crossman, b-d-N4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome, J Virol
Vangeel, Chiu, Jonghe, Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res
Wahl, Gralinski, Johnson, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature
Wai, Chan, Cheung, Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19, Lancet Reg Health West Pac
Wo ¨lfel, Corman, Guggemos, Virological assessment of hospitalized patients with COVID-2019, Nature
Wong, Au, Lau, Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and inhospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the Omicron wave in Hong Kong: an observational study, Lancet
Xie, Bowe, Al-Aly, Molnupiravir and risk of hospital admission or death in adults with Covid-19: emulation of a randomized target trial using electronic health records, BMJ
Xie, Choi, Al-Aly, Molnupiravir and risk of post-acute sequelae of Covid-19: cohort study, BMJ
Yoon, Toots, Lee, Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses, Antimicrob Agents Chemother
